Literature DB >> 15087375

Conditionally replicating adenoviruses expressing short hairpin RNAs silence the expression of a target gene in cancer cells.

Jan E Carette1, Renée M Overmeer, Frederik H E Schagen, Ramon Alemany, Oleg A Barski, Winald R Gerritsen, Victor W Van Beusechem.   

Abstract

RNA interference (RNAi) is a posttranscriptional silencing mechanism triggered by double-stranded RNA that was recently shown to function in mammalian cells. Expression of cancer-associated genes was knocked down by expressing short hairpin RNAs (shRNAs) in cancer cells. By virtue of its excellent target specificity, RNAi may be used as a new therapeutic modality for cancer. The success of this approach will largely depend on efficient delivery of shRNAs to tumor cells. Tumor-selective replication competent viruses are especially suited to efficiently deliver anticancer genes to tumors. In addition, their intrinsic capacity to kill cancer cells makes these viruses promising anticancer agents per se. In this study, conditionally replicating adenoviruses were constructed encoding shRNAs targeted against firefly luciferase. These replicating viruses were shown to specifically silence the expression of the target gene in human cancer cells down to 30% relative to control virus. This finding offers the promise of using RNAi in the context of cancer gene therapy with oncolytic viruses.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15087375     DOI: 10.1158/0008-5472.can-03-3530

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  11 in total

Review 1.  RNA interference: a potent technology in studying and modulating of dendritic cells, and potential in clinical therapy.

Authors:  Fang Cheng; Song He
Journal:  Mol Biol Rep       Date:  2009-09-12       Impact factor: 2.316

Review 2.  Changing faces in virology: the dutch shift from oncogenic to oncolytic viruses.

Authors:  Zineb Belcaid; Martine L M Lamfers; Victor W van Beusechem; Rob C Hoeben
Journal:  Hum Gene Ther       Date:  2014-09-17       Impact factor: 5.695

3.  Inhibitory RNA molecules in immunotherapy for cancer.

Authors:  Chih-Ping Mao; T-C Wu
Journal:  Methods Mol Biol       Date:  2010

4.  Oncolytic adenovirus-mediated short hairpin RNA targeting MYCN gene induces apoptosis by upregulating RKIP in neuroblastoma.

Authors:  Yuan Li; Hongwei Zhang; Xiaoyu Zhu; Dongchuan Feng; Deyong Zhang; Baobiao Zhuo; Junnian Zheng
Journal:  Tumour Biol       Date:  2015-03-04

5.  Expression of RNA interference triggers from an oncolytic herpes simplex virus results in specific silencing in tumour cells in vitro and tumours in vivo.

Authors:  Anna-Maria Anesti; Guy R Simpson; Toby Price; Hardev S Pandha; Robert S Coffin
Journal:  BMC Cancer       Date:  2010-09-13       Impact factor: 4.430

Review 6.  Armed replicating adenoviruses for cancer virotherapy.

Authors:  J J Cody; J T Douglas
Journal:  Cancer Gene Ther       Date:  2009-02-06       Impact factor: 5.987

7.  Adenoviral vector-based strategies for cancer therapy.

Authors:  Anurag Sharma; Manish Tandon; Dinesh S Bangari; Suresh K Mittal
Journal:  Curr Drug ther       Date:  2009-05-01

Review 8.  shRNA-armed conditionally replicative adenoviruses: a promising approach for cancer therapy.

Authors:  Jie Zhang; Meng Ding; Kai Xu; Lijun Mao; Junian Zheng
Journal:  Oncotarget       Date:  2016-05-17

Review 9.  Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides.

Authors:  Rudy Juliano; Md Rowshon Alam; Vidula Dixit; Hyumin Kang
Journal:  Nucleic Acids Res       Date:  2008-06-16       Impact factor: 16.971

10.  Reduced expression of Snail decreases breast cancer cell motility by downregulating the expression and inhibiting the activity of RhoA GTPase.

Authors:  Ali Zhang; Quansheng Wang; Zhiqiang Han; Wei Hu; Ling Xi; Qinlei Gao; Shixuan Wang; Jianfeng Zhou; Gang Xu; Li Meng; Gang Chen; Ding Ma
Journal:  Oncol Lett       Date:  2013-06-07       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.